Novartis
116.04
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Novartis
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Trade GPT
© 2025 Rockalpha Limited. Todos los Derechos Reservados.
Rockalpha Limited está inscrita en el Registro de Proveedores de Servicios Financieros de Nueva Zelanda (FSP: 1001454). El registro de Proveedores de Servicios Financieros de Rockalpha Limited puede verificarse en el Registro de Proveedores de Servicios Financieros. Rockalpha Limited es miembro del Insurance & Financial Services Ombudsman Scheme, un proveedor independiente de servicios de resolución de disputas. Rockalpha Limited no está autorizada por ningún organismo regulador neozelandés para prestar servicios monetarios o inmobiliarios a clientes, y la inscripción de Rockalpha Limited en el registro neozelandés de proveedores de servicios financieros o su pertenencia al Insurance & Financial Services Ombudsman Scheme no significa que Rockalpha Limited esté sujeta a la regulación o supervisión activa de un organismo regulador neozelandés.Rockalpha Limited está inscrita en el Registro de Proveedores de Servicios Financieros de Nueva Zelanda (FSP: 1001454). El registro de Proveedores de Servicios Financieros de Rockalpha Limited puede verificarse en el Registro de Proveedores de Servicios Financieros. Rockalpha Limited es miembro del Insurance & Financial Services Ombudsman Scheme, un proveedor independiente de servicios de resolución de conflictos.
Rockalpha Limited, operates from its Singapore headquarters at CapitaSky 808, 79 Robinson Road, Singapore 068897, with a regional office at Level 6, Core C, Cyberport 3, 100 Cyberport Road, Hong Kong.